无抽搐电休克治疗以阴性症状为主精神分裂症对照研究.docVIP

无抽搐电休克治疗以阴性症状为主精神分裂症对照研究 　　【摘要】 目的 探讨无抽搐电休克治疗（MECT）对以阴性症状为主的精神分裂症的疗效和安全性。方法 70例以阴性症状为主的精神分裂症患者按住院顺序分为研究组和对照组， 各35例。研究组应用舒必利联合无抽搐电休克治疗， 对照组单用舒必利治疗。以阳性症状量表（SAPS）与阴性症状量表（SANS）评定临床疗效、治疗中出现的副反应量表（TESS）评定不良反应。结果 治疗8 周末， 研究组有效率为79.4%， 对照组为54.3%；两组SAPS、 SANS评分均随着治疗时间的延长持续下降；治疗2 周后研究组SAPS评分较对照组下降更显著；4周后SANS总分及各因子分较对照组下降更显著；差异均具有统计学意义 （P0.05或P0.01）。两组不良反应患者大多可耐受， 或经处理后缓解， 未影响治疗。结论 舒必利联合无抽搐电休克治疗以阴性症状为主的精神分裂症患者效果好， 起效快， 改善阴性症状及其他精神病性症状更为显著， 且安全性高。 　　【关键词】 精神分裂症；阴性症状；无抽搐电休克治疗；舒必利 　　DOI：10.14163/j.cnki.11-5547/r.2015.24.011 　　【Abstract】 Objective To investigate curative effect and safety of modified electric convulsive therapy （MECT） in the treatment of schizophrenia with predominantly negative symptoms. Methods A total of 70 schizophrenia patients with predominantly negative symptoms were divided by admission order into research group and control group， with 35 cases in each group. The research group received sulpiride combined with MECT for treatment， and the control group received sulpiride alone. Scale for assessment of positive symptoms （SAPS） and scale for assessment of negative symptoms （SANS） were used to evaluate clinical effects， and treatment emergent symptom scale （TESS） was used to evaluate adverse reactions. Results At the end of 8-week treatment， the effective rate was 79.4% in the research group， and 54.3% in the control group. Both groups had gradually reduced SAPS and SANS scores along with treatment. After 2 weeks of treatment， the research group had more remarkably decreased SAPS score than the control group. The research group also had more decreased SANS total score and factors scores than the control group after 4 weeks. Their differences all had statistical significance （P0.05 or P0.01）. Adverse reactions in most patients were tolerable in both groups， and some were relieved treatment. They had no influence on treatment. Conclusion Combination of sulpiride and MECT provides excellent effect in treating schizophrenia patients with predominantly negativ